AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38409089 — intervention group
Group type: COMPARATOR
Intervention: Pharmacist delivered QuitAid intervention (no)
Number of subjects: 24
Study 38409129 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Awareness Therapy (BAT) + Pulmonary Rehabilitation (PR)
Number of subjects: 43
Study 38409129 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary Rehabilitation (PR)
Number of subjects: 43
Study 38409229 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA-based NGS analysis (FoundationOne® Liquid CDx)
Number of subjects: 542
Study 38409283 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive intracranial pressure (nICP) monitoring using an optical sensor
Number of subjects: 40
Study 38409283 — intervention group
Group type: COMPARATOR
Intervention: Invasive ICP monitoring
Number of subjects: 40
Study 38409323 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein intake (excess of ∼25 g per meal)
Number of subjects: 0
Study 38409323 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake in excess of ∼22% of dietary energy requirements
Number of subjects: 0
Study 38409323 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine as a key activator of mTOR signalling
Number of subjects: 0
Study 38409332 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived mesenchymal stromal cell (MSC) infusion
Number of subjects: 20
Study 38409332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 38410023 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegAsp
Number of subjects: 196
Study 38410109 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-3 bispecific CD276xCD3 antibody, starting dose of 50 µg, with potential increases up to 800 µg depending on safety review.
Number of subjects: 17
Study 38410109 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-3 bispecific CD276xCD3 antibody at maximum tolerated dose (MTD) after determination, additional 14 patients.
Number of subjects: 17
Study 38410116 — intervention group
Group type: EXPERIMENTAL
Intervention: ELENAGEN (plasmid encoding p62/SQSTM1) in combination with gemcitabine (GEM) 1000 mg/m²
Number of subjects: 0
Study 38410116 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (GEM) 1000 mg/m²
Number of subjects: 0
Study 38410454 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF)
Number of subjects: 0
Study 38410470 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG coherence in LD toddlers
Number of subjects: 55
Study 38410470 — intervention group
Group type: COMPARATOR
Intervention: EEG coherence in TD toddlers
Number of subjects: 55
Study 38410470 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep spindle metrics in LD toddlers
Number of subjects: 55
Study 38410470 — intervention group
Group type: COMPARATOR
Intervention: Sleep spindle metrics in TD toddlers
Number of subjects: 55
Study 38410567 — intervention group
Group type: EXPERIMENTAL
Intervention: S-HITHOC (cytoreductive surgery combined with hyperthermic intrathoracic chemotherapy)
Number of subjects: 37
Study 38410608 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidative hypofractionated radiation therapy (hfRT) using stereotactic body radiotherapy (SBRT) starting from 6.5 Gy ×2 fractions and escalating to 10 Gy ×2 fractions, delivered 1 to 2 months after dCRT and concurrently with durvalumab.
Number of subjects: 32
Study 38410608 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant anti-PD-L1 therapy using durvalumab, delivered concurrently with hfRT.
Number of subjects: 32
Study 38410766 — intervention group
Group type: EXPERIMENTAL
Intervention: Children considered recovered by their parents following hospitalization with SARS-CoV-2-related conditions
Number of subjects: 0
Study 38410766 — intervention group
Group type: COMPARATOR
Intervention: Children reported as not recovered
Number of subjects: 0
Study 38410790 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth app-based self-management program
Number of subjects: 96
Study 38410790 — intervention group
Group type: COMPARATOR
Intervention: Routine care plus placebo app
Number of subjects: 96
Study 38410920 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with durvalumab and tremelimumab
Number of subjects: 40
Study 38410920 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine with immunotherapy (durvalumab and tremelimumab)
Number of subjects: 40
Study 38410942 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 453
Study 38410942 — intervention group
Group type: COMPARATOR
Intervention: Male sex
Number of subjects: 453
Study 38410944 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective percutaneous left ventricular unloading
Number of subjects: 250
Study 38410944 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no planned mechanical circulatory support)
Number of subjects: 250
Study 38410952 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute myocardial injury defined as at least 1 high-sensitivity cardiac troponin T value above the upper reference limit (14 ng/L) with a rise/fall of >20%.
Number of subjects: 1067
Study 38410945 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive management with angiography, revascularization, and guideline-directed medical therapy
Number of subjects: 5179
Study 38410945 — intervention group
Group type: COMPARATOR
Intervention: Initial conservative management with guideline-directed medical therapy alone
Number of subjects: 5179
Study 38410945 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive management
Number of subjects: 5179
Study 38411017 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement containing zinc, vitamins B, calcium, iodine, iron, β-carotene, and folic acid during preconception and pregnancy
Number of subjects: 0
Study 38411017 — intervention group
Group type: COMPARATOR
Intervention: Control supplement containing calcium, iodine, iron, β-carotene, and folic acid
Number of subjects: 0
Study 38411246 — intervention group
Group type: EXPERIMENTAL
Intervention: Age Shock Index (ASI) ≥ 44
Number of subjects: 27312
Study 38411246 — intervention group
Group type: EXPERIMENTAL
Intervention: Age Shock Index (ASI)
Number of subjects: 27312
Study 38411246 — intervention group
Group type: COMPARATOR
Intervention: Shock Index (SI)
Number of subjects: 27312
Study 38411246 — intervention group
Group type: COMPARATOR
Intervention: Global Registry of Acute Coronary Events (GRACE) score
Number of subjects: 27312
Study 38411246 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis in Myocardial Infarction (TIMI) risk index
Number of subjects: 27312
Study 38411348 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Intelligence (AuI) skin cancer screening
Number of subjects: 205
Study 38411348 — intervention group
Group type: COMPARATOR
Intervention: Artificial Intelligence (AI) skin cancer screening
Number of subjects: 205
Study 38411348 — intervention group
Group type: COMPARATOR
Intervention: Dermatologist skin cancer screening
Number of subjects: 205
Study 38411348 — intervention group
Group type: COMPARATOR
Intervention: 3D Total-Body Photography (3D-TBP)
Number of subjects: 205
Study 38411348 — intervention group
Group type: COMPARATOR
Intervention: 2D Total-Body Photography (2D-TBP)
Number of subjects: 205
Study 38411348 — intervention group
Group type: COMPARATOR
Intervention: AI assessment in dermatology
Number of subjects: 205
Study 38411348 — intervention group
Group type: COMPARATOR
Intervention: AI assessment for beginners (<2 years' experience)
Number of subjects: 205
Study 38411348 — intervention group
Group type: COMPARATOR
Intervention: AI assessment for experts (>5 years' experience)
Number of subjects: 205
Study 38411644 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (Roux-en-Y gastric bypass, sleeve gastrectomy, adjustable gastric banding)
Number of subjects: 262
Study 38411644 — intervention group
Group type: COMPARATOR
Intervention: Medical/lifestyle management
Number of subjects: 262
Study 38411644 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 262
Study 38411949 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Compassionate Living (MBCL) training, twice a week for 4 weeks
Number of subjects: 54
Study 38411949 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54
Study 38411964 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridge clinic
Number of subjects: 335
Study 38411964 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 335
Study 38411973 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral valacyclovir 1 gm daily for 1 year
Number of subjects: 527
Study 38411973 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 year
Number of subjects: 527
Study 38412008 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination in people with diabetes
Number of subjects: 7139
Study 38412008 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 vaccination in people without diabetes
Number of subjects: 7139
Study 38412047 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-based clinical decision support intervention for PrEP provision
Number of subjects: 5051
Study 38412047 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5051
Study 38412047 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-based intervention for HIV providers
Number of subjects: 5051
Study 38412047 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-based intervention for non-HIV providers
Number of subjects: 5051
Study 38412310 — intervention group
Group type: EXPERIMENTAL
Intervention: T-PGSadult
Number of subjects: 109
Study 38412310 — intervention group
Group type: EXPERIMENTAL
Intervention: SHBG-PGSadult
Number of subjects: 109
Study 38412408 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Tumor Resection (PTR)
Number of subjects: 393
Study 38412408 — intervention group
Group type: COMPARATOR
Intervention: No Primary Tumor Resection (No PTR)
Number of subjects: 393
Study 38412412 — intervention group
Group type: EXPERIMENTAL
Intervention: Binary amyloid positivity status
Number of subjects: 510
Study 38412412 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous amyloid standardized uptake value ratio
Number of subjects: 510
Study 38412412 — intervention group
Group type: EXPERIMENTAL
Intervention: Binary amyloid
Number of subjects: 510
Study 38412412 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous amyloid
Number of subjects: 510
Study 38412412 — intervention group
Group type: EXPERIMENTAL
Intervention: Global amyloid burden
Number of subjects: 510
Study 38412437 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporary percutaneous coronary interventions for chronic total occlusion (CTO)
Number of subjects: 0
Study 38412543 — intervention group
Group type: EXPERIMENTAL
Intervention: Triadic walking with culturally celebratory social reminiscence, 1-mile 3×/week for 6 months
Number of subjects: 42
Study 38412573 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compassionate touch
Number of subjects: 135
Study 38412573 — intervention group
Group type: COMPARATOR
Intervention: Finger-tapping active control
Number of subjects: 135
Study 38412776 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting frailty trajectories
Number of subjects: 381
Study 38412776 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 381
Study 38412840 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant crural repair during LSG
Number of subjects: 0
Study 38412840 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy alone (control)
Number of subjects: 0
Study 38412900 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated caries scoring system using TRIOS Patient Monitoring software
Number of subjects: 91
Study 38412900 — intervention group
Group type: COMPARATOR
Intervention: Conventional visual and radiographic assessment
Number of subjects: 91
Study 38413147 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose VKA targeting an international normalised ratio of 2.0-3.0
Number of subjects: 718
Study 38413147 — intervention group
Group type: COMPARATOR
Intervention: No oral anticoagulation
Number of subjects: 718
Study 38413153 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive immunophenotyping of the peripheral blood immune compartment and advanced neuroimaging markers of SVD and BBB permeability.
Number of subjects: 200
Study 38413153 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging to assess white matter microstructure.
Number of subjects: 200
Study 38413157 — intervention group
Group type: EXPERIMENTAL
Intervention: LOCK Falls Programme, an evidence-based quality improvement intervention involving front-line care team huddles, data collection through observation, and communication facilitation.
Number of subjects: 8480
Study 38413157 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff survey conducted with 1200 staff members.
Number of subjects: 8480
Study 38413157 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with 80 residents and 400 staff members.
Number of subjects: 8480
Study 38413161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL)
Number of subjects: 0
Study 38413161 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated Eye Mask (HEM)
Number of subjects: 0
Study 38413161 — intervention group
Group type: EXPERIMENTAL
Intervention: Vectored Thermal Pulsation System (VTPS)
Number of subjects: 0
Study 38413161 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyelid Massage Device (EMD)
Number of subjects: 0
Study 38413184 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality hypnosis (group VRH)
Number of subjects: 60
Study 38413184 — intervention group
Group type: COMPARATOR
Intervention: Standard care (group control)
Number of subjects: 60
Study 38413246 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab combination therapy
Number of subjects: 35
Study 38413410 — intervention group
Group type: EXPERIMENTAL
Intervention: Asunercept (APG101) treatment
Number of subjects: 12
Study 38413420 — intervention group
Group type: EXPERIMENTAL
Intervention: DEB-TACE using epirubicin-loaded microspheres (≤ 100 μm)
Number of subjects: 108
Study 38413458 — intervention group
Group type: EXPERIMENTAL
Intervention: nn-2D-IOUS
Number of subjects: 99
Study 38413540 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal DHE powder (STS101) 5.2 mg
Number of subjects: 36
Study 38413540 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal DHE powder (STS101) 7.0 mg
Number of subjects: 36
Study 38413540 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal DHE powder (STS101) 8.6 mg
Number of subjects: 36
Study 38413540 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular DHE mesylate 1.0 mg
Number of subjects: 36
Study 38413540 — intervention group
Group type: COMPARATOR
Intervention: Liquid nasal spray DHE 2.0 mg
Number of subjects: 36
Study 38413587 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Number of subjects: 57
Study 38413587 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS
Number of subjects: 57
Study 38413587 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial signals
Number of subjects: 57
Study 38413796 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant and everolimus
Number of subjects: 57
Study 38413849 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic beta-blocker therapy
Number of subjects: 106
Study 38413849 — intervention group
Group type: COMPARATOR
Intervention: Non-beta-blocker therapy
Number of subjects: 106
Study 38413871 — intervention group
Group type: EXPERIMENTAL
Intervention: High intraoperative mechanical power
Number of subjects: 218
Study 38413871 — intervention group
Group type: COMPARATOR
Intervention: Traditional mechanical ventilation variables
Number of subjects: 218
Study 38413930 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells (MSCs) plus basiliximab
Number of subjects: 130
Study 38413930 — intervention group
Group type: COMPARATOR
Intervention: Basiliximab alone (Control)
Number of subjects: 130
Study 38413986 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg/day)
Number of subjects: 158
Study 38413986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 38413990 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain intervention (MD-Int)
Number of subjects: 125
Study 38413990 — intervention group
Group type: COMPARATOR
Intervention: Regular health advice (RHA)
Number of subjects: 125
Study 38413997 — intervention group
Group type: EXPERIMENTAL
Intervention: Prelacteal feeding (PLF)
Number of subjects: 3332
Study 38413997 — intervention group
Group type: COMPARATOR
Intervention: No prelacteal feeding
Number of subjects: 3332
Study 38414003 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CrM) supplementation at 20 g/day
Number of subjects: 20
Study 38414045 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing genetic services (Arm A)
Number of subjects: 360
Study 38414045 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone genetic services (Arm B)
Number of subjects: 360
Study 38414045 — intervention group
Group type: COMPARATOR
Intervention: Usual care services (Arm C)
Number of subjects: 360
Study 38414067 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous UC-MSC infusion
Number of subjects: 0
Study 38414067 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal UC-MSC infusion
Number of subjects: 0
Study 38414126 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 0
Study 38414426 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer surgery
Number of subjects: 3297
Study 38414426 — intervention group
Group type: EXPERIMENTAL
Intervention: Sternotomy
Number of subjects: 3297
Study 38414426 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 3297
Study 38414426 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis surgery
Number of subjects: 3297
Study 38414426 — intervention group
Group type: EXPERIMENTAL
Intervention: All types of surgery
Number of subjects: 3297
Study 38414426 — intervention group
Group type: EXPERIMENTAL
Intervention: CPSP
Number of subjects: 3297
Study 38414426 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative pain
Number of subjects: 3297
Study 38414426 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe CPSP
Number of subjects: 3297
Study 38414510 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab immunotherapy
Number of subjects: 12
Study 38414555 — intervention group
Group type: EXPERIMENTAL
Intervention: IA-tirofiban
Number of subjects: 502
Study 38414555 — intervention group
Group type: EXPERIMENTAL
Intervention: IV-tirofiban
Number of subjects: 502
Study 38414555 — intervention group
Group type: EXPERIMENTAL
Intervention: IA+IV-tirofiban
Number of subjects: 502
Study 38414555 — intervention group
Group type: COMPARATOR
Intervention: non-tirofiban
Number of subjects: 502
Study 38414563 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital physiotherapy intervention over 4 weeks
Number of subjects: 32
Study 38414563 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital physiotherapy intervention
Number of subjects: 32
Study 38414658 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) administration prior to photodynamic therapy (PDT)
Number of subjects: 13
Study 38414886 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy eating and activity intervention embedded in a national home visiting program (Parents as Teachers)
Number of subjects: 276
Study 38414923 — intervention group
Group type: EXPERIMENTAL
Intervention: SeQuent® crystalline sirolimus-coated balloon (SCB)
Number of subjects: 126
Study 38415370 — intervention group
Group type: EXPERIMENTAL
Intervention: Elranatamab
Number of subjects: 123
Study 38415370 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice of treatment (PCT)
Number of subjects: 123
Study 38415722 — intervention group
Group type: EXPERIMENTAL
Intervention: Radar-based home sleep apnea test (HSAT)
Number of subjects: 28
Study 38415722 — intervention group
Group type: COMPARATOR
Intervention: Single measurement
Number of subjects: 28
Study 38415722 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple measurements (5 measurements)
Number of subjects: 28
Study 38415785 — intervention group
Group type: EXPERIMENTAL
Intervention: Enpatoran (100, 200, and 300 mg orally administered)
Number of subjects: 0
Study 38415785 — intervention group
Group type: EXPERIMENTAL
Intervention: Enpatoran
Number of subjects: 0
Study 38415785 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldehyde oxidase (AOX) function
Number of subjects: 0
Study 38415895 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus drug coated balloon (DCB)
Number of subjects: 757
Study 38416143 — intervention group
Group type: EXPERIMENTAL
Intervention: C-PRIME digital health promotion intervention
Number of subjects: 13
Study 38416176 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic artery embolization (PAE)
Number of subjects: 9
Study 38416223 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (8 mg THC for a 75-kg person)
Number of subjects: 48
Study 38416223 — intervention group
Group type: EXPERIMENTAL
Intervention: THC + CBD (8 mg THC and 24 mg CBD for a 75-kg person)
Number of subjects: 48
Study 38416223 — intervention group
Group type: COMPARATOR
Intervention: PLA (matched placebo)
Number of subjects: 48
Study 38416237 — intervention group
Group type: EXPERIMENTAL
Intervention: Faricimab treatment
Number of subjects: 46
Study 38416256 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic MRI segmentation using nnU-Net
Number of subjects: 0
Study 38416256 — intervention group
Group type: COMPARATOR
Intervention: Manual segmentation
Number of subjects: 0
Study 38416256 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning classifier system for liver herniation prediction
Number of subjects: 0
Study 38416313 — intervention group
Group type: EXPERIMENTAL
Intervention: Unplugged Program (intervention arm)
Number of subjects: 1874
Study 38416313 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention arm)
Number of subjects: 1874
Study 38416391 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 102
Study 38416398 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Physical Performance Battery (SPPB)
Number of subjects: 1198
Study 38416430 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple hysterectomy
Number of subjects: 700
Study 38416430 — intervention group
Group type: COMPARATOR
Intervention: Radical hysterectomy
Number of subjects: 700